Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Entertainment Wire Massachusetts.
Press releases published on May 12, 2025
“The Last Human Driver”: Former Wall Street Icon Says Musk’s Dojo Signals the Final Chapter for Man Behind the Wheel
GlobeNewswire
·
May 12, 2025
BALTIMORE, May 12, 2025 (GLOBE NEWSWIRE) -- According to technology analyst Enrique Abeyta, the era of the human driver is nearing its end. The machine that could finally replace them? Elon Musk’s self-training AI supercomputer, Dojo. Set to power Tesla’s …
Paytronix Upgrades In-App Navigation for Guests with Interstitials, Deep Linking Messages
GlobeNewswire
·
May 12, 2025
NEWTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Paytronix, the leader in guest engagement for restaurants and convenience stores, today announced the launch of two new features to its branded mobile app: interstitial messages and deep linking push and pull …
ElevateBio Appoints Ger Brophy, Ph.D., as Interim Chief Executive Officer and Member of the Board of Directors
GlobeNewswire
·
May 12, 2025
Industry veteran brings over 30 years of experience driving technical, operational, and commercial excellence Has served as ElevateBio’s strategic advisor over the past year, working closely with the executive team to scale business and operations WALTHAM, …
IBN Announces CryptoNewsAudio Production Featuring Andrew Gordon, Managing Attorney of Gordon Law Group
GlobeNewswire
·
May 12, 2025
AUSTIN, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- IBN, a multifaceted communications organization, is pleased to announce the release of the latest CryptoNewsAudio Production as part of its sustained effort to provide specialized content distribution via …
Collegium Announces $25 Million Accelerated Share Repurchase Program
GlobeNewswire
·
May 12, 2025
STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it …
ABLi Therapeutics Launches with a Focus on Developing Treatments for Neurodegenerative Diseases that Arise from Activation of c-Abl Kinases
GlobeNewswire
·
May 12, 2025
Lead candidate Risvodetinib (ABLi-148009) is an oral, once-daily, potent, brain-penetrant, selective c-Abl kinase inhibitor that is the first to drive clearance of disease pathology in human Parkinson’s disease ABLi’s proprietary Re-engineering Approach …
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
GlobeNewswire
·
May 12, 2025
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that data from its First-In- …
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
GlobeNewswire
·
May 12, 2025
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders …
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
GlobeNewswire
·
May 12, 2025
Multiple HCPs have requested from Invivyd a monoclonal antibody (mAb) for treatment of active measles infection and post-exposure prophylaxis to reduce the consequence of outbreaks. Such a medicine could accelerate the pathway to functional eradication of …
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
May 12, 2025
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway …
Sionna Therapeutics Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated Phase 1 topline data anticipated this quarter On track to initiate Phase 2a proof-of-concept trial and at least one dual combination …
Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling First patient dosed in Phase 1b trial of APG777 in mild-to-moderate asthma with readout expected in 1H 2026 …
Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody, in Patients with Mild-to-Moderate Asthma
GlobeNewswire
·
May 12, 2025
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53% APG808 demonstrated the potential for durable disease …
Thermosome Receives U.S. Orphan Drug Designation for Lead Compound THE001, Expands Patent Estate
GlobeNewswire
·
May 12, 2025
ODD granted for the treatment of soft tissue sarcomas (STS) Thermosome adds 4 patents to its growing patent estate Munich, Germany – May 12, 2025 – Thermosome, a drug development company focused on targeted tumor therapies, today announced that its lead …
Aeon Media Relaunches Psyche.co, Further Elevating the Standard for Psychology and Wellbeing Content Online
GlobeNewswire
·
May 12, 2025
LONDON, May 12, 2025 (GLOBE NEWSWIRE) -- Psyche.co, Aeon Media’s unique and free digital magazine for thoughtful exploration of psychology and the human experience, is excited to announce the relaunch of its website on 12 May 2025. Amid a landscape …